Three South Korean pharmaceutical firms will soon be allowed to produce generic versions of the anti-impotence drug Viagra despite a row over patents, officials said Wednesday. The Korea Food and Drug Administration said generic products made by the three local firms have passed a \"bioequivalence\" test. \"The three firms are expected to get approval for production of Viagra generics probably this month or later,\" an official in charge of medicine tests told AFP on condition of anonymity. \"Our move has nothing to do with an ongoing patent row,\" he said, adding the watchdog is also expected to give the go ahead for more local firms. Numerous domestic pharmaceutical firms have applied for approval to manufacture Viagra generics since it was introduced in South Korea in 1999. US pharmaceutical giant Pfizer claims its patent, which involves using sildenafil, is valid until May 2014. \"Our patent covering the material is still valid,\" a Pfizer official in Seoul said, urging South Korean firms to recognise it. Pfizer has yet to counter a lawsuit filed by CJ Cheiljedang, a domestic pharmaceutical firm seeking to invalidate the patent. \"We plan to produce a generic Viagra regardless of the court\'s ruling, even if we have to compensate Pfizer in the future,\" an unnamed CJ Cheiljedang official told Yonhap news agency.
GMT 14:01 2018 Thursday ,30 August
Expat with rare heart disorder gets life-saving surgeryGMT 00:18 2018 Tuesday ,23 January
Boy with 10-pound tumour on face diesGMT 21:23 2018 Monday ,22 January
All set for first global medical tourism conference in DubaiGMT 22:46 2018 Sunday ,21 January
Second face transplant for FrenchmanGMT 07:51 2018 Saturday ,20 January
Trio aquitted of negligence in Canada railway disasterGMT 10:57 2018 Thursday ,18 January
Breastfeeding for 6 months cuts diabetes risk in half: studyGMT 16:10 2018 Wednesday ,17 January
Child mummy in Italy had hepatitis, not smallpoxGMT 18:36 2018 Tuesday ,16 January
Greece strikes cause transport chaos, healthcare delays

Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2025 ©
Send your comments
Your comment as a visitor